These data suggest that the majority of hemolysis events had a possible pharmacodynamic influence on this challenging patient population, for whom the PEGASUS study represented one of the first opportunities to manage suboptimal responders to C5 inhibition with a novel proximal complement inhibitor therapy in PNH. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.